On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...